Novo’s troubled Indiana plant claims another victim as FDA rejects Incyte’s lung cancer application
Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz
